Quantcast

Latest Cancer vaccine Stories

2014-02-11 12:26:43

Recurrent lung cancer responds to Integrative Immunotherapy SCOTTSDALE, Ariz., Feb. 11, 2014 /PRNewswire/ -- Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. To view the multimedia assets associated with this release, please visit...

2014-02-06 08:28:58

BETHESDA, Md., Feb. 6, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the BIO CEO and Investor Conference 2014, which is being held in New York on February 10-11, 2014. NW Bio's presentation will take place on Monday, February 10, at 11:30 a.m. EST in the Basildon Room at the Waldorf-Astoria in New York...

2014-02-05 08:28:16

THOUSAND OAKS, Calif., Feb. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Merck, known as MSD outside the United States and Canada, announced today that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a Phase 1b/2 study of patients with mid- to late-stage melanoma. "Talimogene laherparepvec has...

2014-02-04 12:28:11

WORCESTER, Mass. and TORONTO, Feb. 4, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that an interview of Dr. Eric von Hofe, PhD, President of the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), conducted by Stock News Now at last month's J.P. Morgan Healthcare Conference in San Francisco, is now available online. The interview is in respect of the ongoing Phase II trial of the Antigen Express...

2014-02-03 08:28:23

DUBLIN, Ireland, February 3, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/v6rrkv/vaccine_market_by) has announced the addition of the "Concise Analysis of the International Vaccine Market - Global Forecasts To 2022" [http://www.researchandmarkets.com/research/v6rrkv/vaccine_market_by ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global vaccine technology market is...

2014-02-02 23:00:43

MarketReportsOnline.com adds “US Cancer Vaccine Market Outlook 2018” report to its research store. US cancer vaccine market is expected to grow at a CAGR of 10% to surpass USD 20 billion by 2018. Dallas, Texas (PRWEB) February 02, 2014 Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines...

2014-01-29 16:28:12

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in) has announced the addition a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery remains a challenge in management of cancer. Approximately 12.5...

2014-01-13 12:26:52

WORCESTER, Mass. and TORONTO, Jan. 13, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced completion of enrollment of the Antigen Express, Inc. (www.antigenexpress.com) AE37 breast cancer immunotherapy trial. The clinical trial is designed to assess the ability of AE37 to reduce the risk of relapse in patients who have had breast cancer. While a pre-planned primary efficacy analysis is underway, completion of enrollment sets the...

2014-01-13 08:26:16

LOS ANGELES, Jan. 13, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today provided an update on the Company's anticipated 2014 corporate strategies and milestones. (Logo: http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO) "2013 was an eventful year for ImmunoCellular Therapeutics," said Andrew Gengos, ImmunoCellular's Chief Executive Officer. "It was a year of progress, and some challenges - quite typical for a development-stage...

2014-01-09 12:26:33

BETHESDA, Md., Jan. 9, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the Biotech Showcase(TM) 2014 Conference that is being held in San Francisco from January 13-15, 2014. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) NW Bio's presentation will take place on Monday, January 13, at...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.